Evaluation of aberrant expression of CD markers in acute leukemia cells


  • Lava kareem Shwani Department of Basic Sciences, College of Medicine, Hawler Medical University, Erbil, Iraq.
  • Nawsherwan Sadiq Muhammad Department of Basic Sciences, College of Medicine, Hawler Medical University, Erbil, Iraq.
  • Hiwa Hassan Hamza Department of Laboratory, Flow Cytometry Unit, Nanakaly Hospital for Blood Diseases, Erbil, Iraq.




Aberrant phenotype, Flow cytometry, Acute leukemia, AML, B-ALL, T-ALL


Background and objective: Worldwide immunophenotyping by flow cytometry (FCM) in acute leukemia (AL) is the golden step in the diagnosis. It’s very common for acute leukemias to aberrantly express antigens or cluster of differentiation (CD) markers which are usually expressed in other lineages of the disease hence this study aimed at determining the prevalence of aberrancy in AL and to find out the frequency of each aberrant CD marker and their association with the clinic-hematological profile of the cases.

Methods: Following history and clinical examination of enrolled patients, blood and/or bone marrow aspirate was drawn for morphological examination and immunophenotyping by FCM from 86 newly diagnosed acute leukemia cases then multiple steps procedure was applied followed by interpretation of the results.

Results: The prevalence of aberrant phenotype was 46.5%. The proportional frequency of aberrant phenotype in acute myeloid leukemia (AML) was 41%, in B-acute lymphoblastic leukemia (B-ALL) was 48.8% and in T-acute lymphoblastic leukemia (T-ALL) was 66.6%. The commonest aberrant CD markers in AML were CD22 and CD2, in B-ALL were CD66c and CD13 while in T-ALL were CD13 and CD33. The aberrant phenotype harbored lower white blood cell (WBC) count and blast percentage in PB, also splenomegaly was more frequent in lymphoid positive (Ly+) AML and myeloid positive (My+) T-ALL while in B-ALL, splenomegaly was more frequent in myeloid negative (My-) B-ALL.

Conclusion: Aberrant phenotype prevalence in our study sample was comparable to other studies, considerable frequency of aberrant markers is present in cases of AL and some variations exist regarding the clinical and hematological profile of the aberrant group.


Metrics Loading ...

Author Biography

Nawsherwan Sadiq Muhammad, Department of Basic Sciences, College of Medicine, Hawler Medical University, Erbil, Iraq.

Hawler Medical University, College of Medicine, Pathology department, Erbil, Iraq


Othman GO, Mohammad NS, Saeed CH. Molecular study of Nucleophosmin 1 (NPM1) gene in acute myeloid leukemia in Kurdish population. Afr Health Sci. 2021; 21(2):687–92. doi:10.4314/ahs.v21i2.26

Pouls RK, Shamoon RP, Muhammed NS. Clinical and haematological parameters in adult AML patients: a four year experience at Nanakaly Hospital for blood diseases. Zanco J Med Sci. 2012; 16(3):199–203. https://doi.org/10.15218/zjms.2012.0035

Jahan N, Sattar H, Tarafder S, Roy CK, Rahman I, Johora FT. Aberrant Antigen Expression in Children with Acute Leukemia A Flow Cytometric Analysis. Bangladesh J Med Microbiol 2018; 12(1):10–4. https://doi.org/10.3329/bjmm.v12i1.51685

Sarma A, Hazarika M, Das D, Kumar Rai A, Sharma JD, Bhuyan C, et al. Expression of aberrant CD markers in acute leukemia: A study of 100 cases with immunophenotyping by multiparameter flowcytometry. Cancer Biomark. 2015; 15(4):501–5. doi:10.3233/CBM-150482

Pinheiro LH, Trindade LD, de Oliveira Costa F, de Lima Silva N, Sandes AF, Nunes MA, et al. Aberrant Phenotypes in Acute Myeloid Leukemia and Its Relationship with Prognosis and Survival: A Systematic Review and Meta-Analysis. Int J Hematol Oncol Stem Cell Res. 2020; 14(4):274. doi:10.18502/ijhoscr.v14i4.4484

Al-Anizi WM, Al-Mashta MA. The frequency of aberrant lymphoid antigens expression in 202 Iraqi patients with de novo acute myeloid leukemia. Iraqi J Hematol. 2017; 6(2):49. doi:10.4103/ijh.ijh_17_17

Ibrahim AM, Hameed BM. Prognostic value of myeloid antigens expression in childhood acute lymphoblastic leukemia. Iraqi J Hematol. 2017; 6(1):12. doi:10.4103/ijh.ijh_5_17

Abdullah NF, Wafa AE, Ahmed H, Allam AA, Mohamed AM. Aberrant Expression of CD Markers in Cases with Acute Leukemia in Sohag University Hospital. SMJ. 2018; 22(2):287–95. doi:10.21608/smj.2018.40953

Abdulateef NA, Ismail MM, Aljedani H. Clinical significance of co-expression of aberrant antigens in acute leukemia: a retrospective cohort study in Makah Al Mukaramah, Saudi Arabia. Asian Pac J Cancer Prev. 2014; 15(1):221–7. https://doi.org/10.7314/APJCP.2014.15.1.221

Lopes TC, Andrade KN, Camelo NL, Rodrigues VP, Oliveira RA. Influence of aberrant myeloid expression on acute lymphoblastic leukemia in children and adolescents from Maranhão, Brazil. Genet Mol Res. 2014; 13(4):10301–7. doi:10.4238/2014.December.4.25

Bene MC, Nebe T, Bettelheim P, Buldini B, Bumbea H, Kern W, et al. Immunophenotyping of acute leukemia and lymphoproliferative disorders: a consensus proposal of the European Leukemianet work package 10. Leukemia. 2011; 25:567–74. doi:10.1038/leu.2010.312

Swerdlow S, Campo E, Harris N, Jaffe E, Pileri S, Stein H, et al. WHO Classification of Haematopoietic and Lymphoid Tissues. 4th ed. Lynon:IARC; 2017.

Mohamed MA, Shafik EA, Ahmed AO, Sayed DM. Expression of aberrant markers in acute leukemia at south Egypt cancer institute: A retrospective study. SECI Oncol. 2021; 9:53–63.

Momani A, Abbasi N, Alsokhni H, Habahbeh L, Khasawneh R, Kamal N. Aberrant antigen expression in patients with acute leukemias; experience of King Hussein Medical Center in Jordan. JRMS. 2016; 23(2):59–67. doi:10.12816/0027107

Hussein GA, Jawad AM. Impact of aberrant antigens expression on remission rate after first induction course of chemotherapy in de novo adult acute myeloid leukemia. Iraqi J Hematol. 2021; 10(2):118–122. doi:10.4103/ijh.ijh_17_21

Ahuja S, Malviya A. Spectrum of immunophenotypic aberrancies in acute leukemia along with their correlation with adverse hematological parameters. Indian J Health Sci Biomed Res. 2022; 15(1):76. doi:10.4103/kleuhsj.kleuhsj_170_21

Gupta M, Monga L, Mehrotra D, Chhabra S, Singhal S, Sen R. Immunophenotypic aberrancies in acute leukemia: A tertiary care centre experience. Oman Med J. 2021; 36(1):e218. doi:10.5001/omj.2021.03

Tipu HN, Muhammad MB, Altaf C, Noman M, Malik HS. Spectrum of acute leukemias and aberrant markers expression based on flowcytometry in a tertiary care centre. PAFMJ. 2018; 68(3):450–4.

Sharma M, Varma N, Sachdeva MU, Bose P, Varma S. Clinical and hematological correlates of aberrant immunophenotypic profiles in adult and pediatric acute myeloid leukemia at presentation. J Cancer Res Ther. 2020; 16(1):105–9. doi:10.4103/jcrt.JCRT_770_17

Jahedi M, Shamsasenjan K, Sanaat Z, Aliparasti M, Almasi S, Mohamadian M, et al. Aberrant phenotype in Iranian patients with acute myeloid leukemia. Adv Pharm Bull. 2014; 4(1):43–7. doi:10.5681/apb.2014.007

Muhsin SY, Al-Mudallal SS. Expression of Aberrant Antigens CD7 and CD19 in Adult Acute Myeloid Leukemia by Flow Cytometry. Iraqi J Hematol. 2014; 3(1):1–13.

Mahmoud MS, Abd Elhafeez HA, Abd Elmouez SM. Verification of aberrant expression of CD7 in acute myeloid leukemia. Curr Med Res Prac. 2020; 5(2):133–40. doi:10.4103/JCMRP.JCMRP_115_18

Chughtai O, Chughtai A. Aberrant expression of CD markers in acute leukemia. Ann Pak Inst Med Sci. 2013; 9(2):99-102.

Shahni A, Saud M, Siddiqui S, Mukry SN. Expression of aberrant antigens in hematological malignancies: A single center experience. Pak j Med Sci. 2018; 34(2):457–62. doi:10.12669/pjms.342.13996

Aref S, Abousamara N, El-Helaly E, Mabed M. Clinical significance of CD200 and CD56 expression in patients with acute myeloid leukemia. Asian Pac J Cancer Prev. 2020; 21(3):743–8. doi:10.31557/APJCP.2020.21.3.743

Jalal SD, Al-Allawi NA, Al Doski AA. Immunophenotypic aberrancies in acute lymphoblastic leukemia from 282 Iraqi patients. Int J Lab Hematol. 2017; 39(6):625–32. https://doi.org/10.1111/ijlh.12716

Sharma M, Sachdeva MU, Varma N, Varma S, Marwaha RK. Characterization of immunophenotypic aberrancies in adult and childhood acute lymphoblastic leukemia: A study from Northern India. J Can Res Ther. 2016; 12(2):620–6. doi:10.4103/0973-1482.147716

Ibrahim AM, Hameed BM. Prognostic value of myeloid antigens expression in childhood acute lymphoblastic leukemia. Iraqi J Hematol. 2017; 6(1):12–16. doi:10.4103/ijh.ijh_5_17

Tang GS, Wu J, Liu M, Chen H, Gong SG, Yang J, et al. BCR-ABL1 and CD66c exhibit high concordance in minimal residual disease detection of adult B-acute lymphoblastic leukemia. Am J of Transl Res. 2015; 7(3):632–9. PMC4448202

Jain S, Mehta A, Kapoor G, Bhurani D, Jain S, Agrawal N, et al. Evaluating new markers for minimal residual disease analysis by flow cytometry in precursor B lymphoblastic leukemia. Indian J Hematol Blood Transfus. 2018; 34(1):48–53. doi:10.1007/s12288-017-0845-5

Hamid GA, Akrabi A. Aberrant antigen expression in patients with acute leukemia. EC Clin Med Case Report. 2019; 53–60.

Hoffbrand A, Steensma D. Hoffbrand`s Essential Haematology. 8th ed.UK: John Wiley & Sons Ltd; 2020.

Tong H, Wang H, Wang Q, Liu Z, Lu C. Immunophenotypic, cytogenetic and clinical features in Chinese adult acute lymphoblastic leukaemia (ALL) patients. Ann Acad Med Singapore. 2014; 43(3):152–9.




How to Cite

kareem Shwani, L. ., Sadiq Muhammad, N. ., & Hassan Hamza, H. . (2023). Evaluation of aberrant expression of CD markers in acute leukemia cells. Zanco Journal of Medical Sciences (Zanco J Med Sci), 27(2), 194–204. https://doi.org/10.15218/zjms.2023.022



Original Articles